O. Bortone , S. Fiorenza , M. Baldassarre , N. Falco , M. Amidi , T. Markkula , P.A. Netti , E. Torino
{"title":"Design of a thermal stress microfluidic platform to screen stability of therapeutic proteins in pharmaceutical formulations","authors":"O. Bortone , S. Fiorenza , M. Baldassarre , N. Falco , M. Amidi , T. Markkula , P.A. Netti , E. Torino","doi":"10.1016/j.crbiot.2025.100273","DOIUrl":null,"url":null,"abstract":"<div><div>Therapeutic proteins have great potentialities for the care of a wide spectrum of diseases, for which other small synthetic drugs result ineffective. Due to challenges related to their immunogenicity, the journey of biologics into clinics still faces obstacles. Among the causes of protein immunogenicity, their natural propensity to aggregation is crucial, indeed, to study their stability, pharmaceutical formulations are generally exposed to diverse environmental physicochemical conditions. Traditional approaches to explore protein behavior are effort-demanding, lengthy and expensive, resulting in a limited knowledge of biomolecule stability. There is an urgent need to develop faster and more cost-effective technologies for biological formulation development. In this work, the conceptualization, design and implementation of a modular and automated microfluidic platform to provide thermal stress to highly concentrated and viscous pharmaceutical formulations is presented. The microfluidic platform validity in terms of reliability and comparability to a forced degradation batch-wise stimulation is demonstrated by thermally stimulating and analyzing through SE-HPLC (Size Exclusion – High Performance Liquid Chromatography) different high concentration (> 100 mg/ml) therapeutic nanobody-based formulations. Remarkably, the ranking of the formulations returned by the microfluidic thermal stress platform follows the same trend obtained through well-established industrial in-batch stimulations. Furthermore, data coming from microfluidic stimulations well correlates to outcomes coming from industrial methodologies for storage and accelerated stability studies.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"9 ","pages":"Article 100273"},"PeriodicalIF":3.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590262825000024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Therapeutic proteins have great potentialities for the care of a wide spectrum of diseases, for which other small synthetic drugs result ineffective. Due to challenges related to their immunogenicity, the journey of biologics into clinics still faces obstacles. Among the causes of protein immunogenicity, their natural propensity to aggregation is crucial, indeed, to study their stability, pharmaceutical formulations are generally exposed to diverse environmental physicochemical conditions. Traditional approaches to explore protein behavior are effort-demanding, lengthy and expensive, resulting in a limited knowledge of biomolecule stability. There is an urgent need to develop faster and more cost-effective technologies for biological formulation development. In this work, the conceptualization, design and implementation of a modular and automated microfluidic platform to provide thermal stress to highly concentrated and viscous pharmaceutical formulations is presented. The microfluidic platform validity in terms of reliability and comparability to a forced degradation batch-wise stimulation is demonstrated by thermally stimulating and analyzing through SE-HPLC (Size Exclusion – High Performance Liquid Chromatography) different high concentration (> 100 mg/ml) therapeutic nanobody-based formulations. Remarkably, the ranking of the formulations returned by the microfluidic thermal stress platform follows the same trend obtained through well-established industrial in-batch stimulations. Furthermore, data coming from microfluidic stimulations well correlates to outcomes coming from industrial methodologies for storage and accelerated stability studies.
期刊介绍:
Current Research in Biotechnology (CRBIOT) is a new primary research, gold open access journal from Elsevier. CRBIOT publishes original papers, reviews, and short communications (including viewpoints and perspectives) resulting from research in biotechnology and biotech-associated disciplines.
Current Research in Biotechnology is a peer-reviewed gold open access (OA) journal and upon acceptance all articles are permanently and freely available. It is a companion to the highly regarded review journal Current Opinion in Biotechnology (2018 CiteScore 8.450) and is part of the Current Opinion and Research (CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.